In summary, our results show that the overexpression of RUNX2 in lung cancer is related to its occupancy at different genomic regions, principally at intergenic regions (61%), introns (29%), and promoters-transcription start sites (TSSs) (5%). This evidence concerns the gene RUNX2 and lung carcinoma.